Stay updated on Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page
- Check6 days agoChange DetectedMinimal layout and typography adjustments to the Study Details page with no changes to core content; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check13 days agoNo Change Detected
- Check35 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference4%

- Check42 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision: v3.0.2 replaces v3.0.1, and the 'Back to Top' element has been removed.SummaryDifference0.2%

- Check63 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check71 days agoChange DetectedThe web page has added a facility name and location related to Hemic and Lymphatic Diseases, specifically mentioning Lymphoma, Follicular, and pembrolizumab, while removing various related terms and resources.SummaryDifference4%

Stay in the know with updates to Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.